Chronic morphine therapy for cancer pain: Plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations Journal Article


Authors: Portenoy, R. K.; Khan, E.; Layman, M.; Lapin, J.; Malkin, M. G.; Foley, K. M.; Thaler, H. T.; Cerbone, D. J.; Inturrisi, C. E.
Article Title: Chronic morphine therapy for cancer pain: Plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations
Abstract: Morphine-6-glucuronide (M-6-G) is an active metabolite that may contribute to the clinical effects produced by systemic administration of morphine. To help clarify the extent to which M-6-G may cross the blood-brain barrier and exert effects, we employed high-performance liquid chromatography with electrochemical detection to measure the concentrations of M-6-G and morphine in the plasma and either ventricular (three patients) or lumbar (eight patients) CSF of cancer patients receiving chronic morphine therapy. The mean ratio of morphine in ventricular CSF: morphine in plasma was 0.71; the same ratio for M-6-G was only 0.077. The average molar ratio of M-6-G: morphine in ventricular CSF was 0.207, and the average molar ratio in plasma was 1.89. Although sampling problems render the lumbar CSF results less reliable, they were very similar. Thus, plasma contained approximately twice as much M-6-G as morphine, whereas CSF contained only one-fifth to one- third as much. These data confirm that M-6-G in plasma is distributed into CSF, but to a far lesser extent than morphine. They help explain animal data demonstrating much higher potency of M-6-G on administration into CSF than systemic administration and indicate that the degree to which M-6-G contributes to morphine effects in humans remains an unresolved question. © 1991 American Academy of Neurology.
Keywords: adult; clinical article; aged; aged, 80 and over; neoplasms; pain; cancer pain; cerebrospinal fluid; morphine; intravenous drug administration; morphine 6 glucuronide; oral drug administration; middle age; morphine derivatives; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title: Neurology
Volume: 41
Issue: 9
ISSN: 0028-3878
Publisher: Lippincott Williams & Wilkins  
Date Published: 1991-09-01
Start Page: 1457
End Page: 1461
Language: English
PUBMED: 1891098
PROVIDER: scopus
DOI: 10.1212/wnl.41.9.1457
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark Malkin
    38 Malkin
  2. Kathleen M Foley
    200 Foley
  3. Howard T Thaler
    245 Thaler
  4. Jeanne   Lapin
    8 Lapin
  5. Russell K. Portenoy
    165 Portenoy